
IMBrave | WO41535
NCT04102098
JCP071
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)
Status:
Recruiting

III
Phase

Adjuvant
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Atezolizumab + Bevacizumab
Treatment Arms
o Experimental: Arm A (atezolizumab plus bevacizumab)
o No Intervention: Arm B (active surveillance)